Navigation Links
CytRx Announces Clinical Results from Its Rising Multiple Dose,Trial with Arimoclomol for ALS

LOS ANGELES--(BUSINESS WIRE)--Jun 25, 2007 - CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today reported safety and tolerability results from its previously announced double-blind, placebo-controlled, rising multiple dose clinical trial in healthy volunteers with its drug candidate arimoclomol. CytRx believes that the results of this trial support the use of arimoclomol in future clinical trials, including its ALS Phase IIb clinical trial, at doses up to six-fold higher than that used in its previous Phase IIa clinical trials for ALS.

CytRx plans to begin its Phase IIb clinical trial in the second half of this year, subject to U.S. Food and Drug Administration (FDA) clearance. As previously announced, this trial, planned to include approximately 390 ALS patients enrolled at 30 to 35 U.S. and Canadian clinical sites, was designed to monitor changes in the progression of disease symptoms and would be completed about 18 months after the beginning of patient enrollment. Following consultation with the FDA, CytRx is now considering various options, including increasing the size and duration of the planned trial and/or conducting a second efficacy clinical trial for ALS, possibly in parallel with the Phase IIb trial, to provide additional data to support a possible approval decision by the FDA.

CytRx expects to announce results of its recently-completed six-month open-label extension trial with arimoclomol for ALS later this week.

"It is rewarding to see significant progress toward our goal of initiating the Phase IIb clinical trial for arimoclomol this year," stated CytRx's President and CEO Steven A. Kriegsman. "Based on the results of this clinical trial we plan to proceed with a dose that is four times greater than that used in our previous Phase IIa ALS clinical trials. These study results will help us optimize
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
2. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
3. CytRx Announces Positive Results of Arimoclomol in Preclinical Stroke Recovery Studies
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:10/22/2014)... -- Investor-Edge has initiated coverage on the ... ), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), ... Pharmaceuticals Inc. (NASDAQ: IDRA ), and Merrimack ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,419.48, up 2.40%, the Dow Jones Industrial ...
(Date:10/22/2014)... RIDGE, N.J. , Oct. 22, 2014 /PRNewswire/ ... (RMANJ), a world-renowned leader in the field of ... rapid approach to embryonic screening. The research abstract, ... Society for Reproductive Medicine (ASRM) meeting in ... screening (CCS) and single gene defect (SGD) pre-implantation ...
(Date:10/22/2014)... Oct. 22, 2014 AVACEN Medical announced today ... 510 (k) OTC clearance by the U.S. Food and ... be marketed over the Internet for: the temporary ... and minor strains and sprains . Logo ... 100 (MSRP $2495) is a sophisticated medical device incorporating ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
(Date:10/25/2014)... (HealthDay News) -- Not getting the right amount of ... new study suggests. Those who sleep less or ... night may be more prone to developing the chronic ... The study authors concluded that duration and quality of ... with inflammatory bowel diseases. "Both short and long ...
(Date:10/25/2014)... A large influx of international aid is needed, and ... thousands of deaths from the widening Ebola crisis, a ... a specially designed mathematical model, the researchers looked at ... densely populated county of hard-hit Liberia -- Montserrado County, ... researchers said that if international aid isn,t delivered to ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... increased risks for certain cancers, one might think that high-risk ... a new study suggests that, at least with colon cancer, ... genes doubled their risk of colon cancer were no more ... "It didn,t make any difference, not at all," said study ...
(Date:10/22/2014)... 22, 2014 At a time when ... parents and athletes at all levels, the UPMC ... the current discussion where two powerful messages are lost: ... that result in full recoveries every day. , In ... in fact and research, UPMC and the Concussion Program ...
(Date:10/22/2014)... Austin, TX (PRWEB) October 22, 2014 ... Criminal Minds featuring skin diseases both fictional ... Foundation (CEHMDF), a nonprofit organization committed to advocacy ... wondering if CBS will take the opportunity to impart ... disease. , There are many misconceptions about ...
Breaking Medicine News(10 mins):Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... SaaS Compliance Manager Enables PHNS and Healthcare Organizations ... ... Regulations, BATON ROUGE, La., Nov. 16 ... with PHNS, making its web-based Compliance Manager available to,hundreds of healthcare ...
... to Improved HIV Management in Developing World, UPPSALA, ... has signed an agreement with a consortium of American ... of operational,funding, and has committed to raising additional funding ... Cavidi,s newly adopted three-year,business plan. Cavidi is the producer ...
... Disclosures for Separate Account J, WASHINGTON, Nov. ... a Department of Labor investigation, launched in 2002,regarding ... of 1974 (ERISA). The Department of Labor ... pension plan, ultimately focused on whether the compensation,arrangements ...
... Sexual Behavior, Sexual Desire, ... WHAT: Are medicine and technology changing human sexuality? Does gender ... in the quality of life of people ... compelling issues on human sexuality will be the focus of ...
... HealthPartners,is the top-performing health plan in the nation ... released business report. The report, sponsored by the,National Business ... for,information tool. The tool is used by purchasers across ... Care Action Group, a coalition of,private and public employers., ...
... - December 31, TULSA, Okla., Nov. 16 ... it will offer three Medicare Part D,prescription drug plans ... Medicare. Medicare beneficiaries in Oklahoma can sign,up for or ... 2008,annual open enrollment period, which begins November 15 and ...
Cached Medicine News:Health News:TraceSecurity Announces Partnership with PHNS Expanding Compliance Services to Hundreds of Healthcare Systems 2Health News:TraceSecurity Announces Partnership with PHNS Expanding Compliance Services to Hundreds of Healthcare Systems 3Health News:New Investors Fund Expansion of Cavidi AB 2Health News:ULLICO Inc. and U.S. Department of Labor Agree to Resolve 5 Year Old ERISA Investigation 2Health News:ULLICO Inc. and U.S. Department of Labor Agree to Resolve 5 Year Old ERISA Investigation 3Health News:Charlie Rose Science Series 2Health News:HealthPartners is National Benchmark in Six Out of Seven Areas in National Business Coalition on Health Report 2Health News:Blue Cross and Blue Shield of Oklahoma Announces Flexible, Affordable Blue MedicareRx(SM) Medicare Prescription Drug Plans 2
... Marco's American standard, corrected curve trial lenses are ... used in Marco refractors and are invaluable in ... sets of other manufacturers contain a disproportionately large ... are less expensive to produce, and fewer lenses ...
... brings new freedom and portability to ... and excellence that are the hallmark ... eyecare practitioners a simple, affordable, and ... utilizes the same proven technology of ...
The Electric H-Base Table is for heavier instruments, or for those who prefer electric elevation. The electric table easily accepts a slit lamp, a single tabletop, or a double tabletop, just as the M...
... or for those seeking high quality ... is an economical, full-function instrument-delivery system. ... body offer rugged, maintenance-free service. And ... two arms provided as standard equipment--adjusts ...
Medicine Products: